Cargando…
Therapie der atopischen Dermatitis mit Dupilumab: Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis
We present the results of a retrospective data analysis of a practice cohort of 44 patients with atopic dermatitis treated with the IL-4/13 receptor antibody dupilumab for up to 3 years. Patients were followed up over a period of 21 months during specialized consultation hours named Immunodermatolog...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323538/ https://www.ncbi.nlm.nih.gov/pubmed/34328514 http://dx.doi.org/10.1007/s00105-021-04868-4 |
_version_ | 1783731261501603840 |
---|---|
author | Jahn, Sigbert Föhr, Julia Diamanti, Evangelia Herbst, Matthias |
author_facet | Jahn, Sigbert Föhr, Julia Diamanti, Evangelia Herbst, Matthias |
author_sort | Jahn, Sigbert |
collection | PubMed |
description | We present the results of a retrospective data analysis of a practice cohort of 44 patients with atopic dermatitis treated with the IL-4/13 receptor antibody dupilumab for up to 3 years. Patients were followed up over a period of 21 months during specialized consultation hours named Immunodermatology, which was established to guarantee comprehensive documentation. The patient’s characteristics regarding age and sex distribution, severity and duration of disease were comparable with the patient collectives in large, pivotal studies. The therapeutic efficiency however was high (percentage of patients with EASI50, -75, -90 after 16 weeks: 94, 84, 60%, respectively) and long lasting (86% EASI90 after 52 weeks on therapy) under everyday conditions in the clinical setting. Approximately half of the patients had facial skin or eye involvement either in their history or at the start of treatment. This group of patients proved to need more and intense care because facial dermatitis and periocular dermatitis, which often involved conjunctivitis, took longer to heal, relapses occurred, and an additional topical treatment was often required. We did not observe any severe side effects during the 48 patient–years analyzed in this study. Dupilumab proved to be a safe and efficient treatment for atopic dermatitis in dermatological practice. |
format | Online Article Text |
id | pubmed-8323538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-83235382021-07-30 Therapie der atopischen Dermatitis mit Dupilumab: Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis Jahn, Sigbert Föhr, Julia Diamanti, Evangelia Herbst, Matthias Hautarzt Originalien We present the results of a retrospective data analysis of a practice cohort of 44 patients with atopic dermatitis treated with the IL-4/13 receptor antibody dupilumab for up to 3 years. Patients were followed up over a period of 21 months during specialized consultation hours named Immunodermatology, which was established to guarantee comprehensive documentation. The patient’s characteristics regarding age and sex distribution, severity and duration of disease were comparable with the patient collectives in large, pivotal studies. The therapeutic efficiency however was high (percentage of patients with EASI50, -75, -90 after 16 weeks: 94, 84, 60%, respectively) and long lasting (86% EASI90 after 52 weeks on therapy) under everyday conditions in the clinical setting. Approximately half of the patients had facial skin or eye involvement either in their history or at the start of treatment. This group of patients proved to need more and intense care because facial dermatitis and periocular dermatitis, which often involved conjunctivitis, took longer to heal, relapses occurred, and an additional topical treatment was often required. We did not observe any severe side effects during the 48 patient–years analyzed in this study. Dupilumab proved to be a safe and efficient treatment for atopic dermatitis in dermatological practice. Springer Medizin 2021-07-30 2021 /pmc/articles/PMC8323538/ /pubmed/34328514 http://dx.doi.org/10.1007/s00105-021-04868-4 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Originalien Jahn, Sigbert Föhr, Julia Diamanti, Evangelia Herbst, Matthias Therapie der atopischen Dermatitis mit Dupilumab: Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis |
title | Therapie der atopischen Dermatitis mit Dupilumab: Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis |
title_full | Therapie der atopischen Dermatitis mit Dupilumab: Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis |
title_fullStr | Therapie der atopischen Dermatitis mit Dupilumab: Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis |
title_full_unstemmed | Therapie der atopischen Dermatitis mit Dupilumab: Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis |
title_short | Therapie der atopischen Dermatitis mit Dupilumab: Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis |
title_sort | therapie der atopischen dermatitis mit dupilumab: eine retrospektive kohortenanalyse aus der dermatologischen praxis |
topic | Originalien |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323538/ https://www.ncbi.nlm.nih.gov/pubmed/34328514 http://dx.doi.org/10.1007/s00105-021-04868-4 |
work_keys_str_mv | AT jahnsigbert therapiederatopischendermatitismitdupilumabeineretrospektivekohortenanalyseausderdermatologischenpraxis AT fohrjulia therapiederatopischendermatitismitdupilumabeineretrospektivekohortenanalyseausderdermatologischenpraxis AT diamantievangelia therapiederatopischendermatitismitdupilumabeineretrospektivekohortenanalyseausderdermatologischenpraxis AT herbstmatthias therapiederatopischendermatitismitdupilumabeineretrospektivekohortenanalyseausderdermatologischenpraxis |